Rupert W Strauss1,2,3,4,5, Beatriz Muñoz1, Alexander Ho6, Anamika Jha6, Michel Michaelides2,3, Artur V Cideciyan7, Isabelle Audo8,9,10,11, David G Birch12, Amir H Hariri6, Muneeswar G Nittala6, SriniVas Sadda6, Sheila West1, Hendrik P N Scholl1,5. 1. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. 2. Moorfields Eye Hospital National Health Service Foundation Trust, London, England. 3. University College London Institute of Ophthalmology, University College London, London, England. 4. Department of Ophthalmology, Medical University Graz and Johannes Kepler University Linz, Linz, Austria. 5. Department of Ophthalmology, University of Basel, Basel, Switzerland. 6. Doheny Eye Institute, David Geffen School of Medicine at University of California-Los Angeles. 7. Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 8. Sorbonne Universités, University Pierre et Marie Curie Université de Paris 06, Paris, France. 9. Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France. 10. Centre National de la Recherche Scientifique, Institut de la Vision, Paris, France. 11. Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France. 12. Retina Foundation of the Southwest, Dallas, Texas.
Abstract
Importance: Sensitive outcome measures for disease progression are needed for treatment trials of Stargardt disease. Objective: To describe the yearly progression rate of atrophic lesions in the retrospective Progression of Stargardt Disease study. Design, Setting, and Participants: A multicenter retrospective cohort study was conducted at tertiary referral centers in the United States and Europe. A total of 251 patients aged 6 years or older at baseline, harboring disease-causing variants in ABCA4 (OMIM 601691), enrolled in the study from 9 centers between August 2, 2013, and December 12, 2014; of these patients, 215 had at least 2 gradable fundus autofluorescence images with atrophic lesion(s) present in at least 1 eye. Exposures: Areas of definitely decreased autofluorescence (DDAF) and questionably decreased autofluorescence were quantified by a reading center. Progression rates were estimated from linear mixed models with time as the independent variable. Main Outcomes and Measures: Yearly rate of progression using the growth of atrophic lesions measured by fundus autofluorescence. Results: A total of 251 participants (458 study eyes) were enrolled. Images from 386 eyes of 215 participants (126 females and 89 males; mean [SD] age, 29.9 [14.7] years; mean [SD] age of onset of symptoms, 21.9 [13.3] years) showed atrophic lesions present on at least 2 visits and were graded for 2 (156 eyes), 3 (174 eyes), or 4 (57 eyes) visits. A subset of 224 eyes (123 female participants and 101 male participants; mean [SD] age, 33.0 [15.1] years) had areas of DDAF present on at least 2 visits; these eyes were included in the estimation of the progression of the area of DDAF. At the first visit, DDAF was present in 224 eyes (58.0%), with a mean (SD) lesion size of 2.2 (2.7) mm2. The total mean (SD) area of decreased autofluorescence (DDAF and questionably decreased autofluorescence) at first visit was 2.6 (2.8) mm2. Mean progression of DDAF was 0.51 mm2/y (95% CI, 0.42-0.61 mm2/y), and of total decreased fundus autofluorescence was 0.35 mm2/y (95% CI, 0.28-0.43 mm2/y). Rates of progression depended on the initial size of the lesion. Conclusions and Relevance: In Stargardt disease with DDAF lesions, fundus autofluorescence may serve as a monitoring tool for interventional clinical trials that aim to slow disease progression. Rates of progression depended mainly on initial lesion size.
Importance: Sensitive outcome measures for disease progression are needed for treatment trials of Stargardt disease. Objective: To describe the yearly progression rate of atrophic lesions in the retrospective Progression of Stargardt Disease study. Design, Setting, and Participants: A multicenter retrospective cohort study was conducted at tertiary referral centers in the United States and Europe. A total of 251 patients aged 6 years or older at baseline, harboring disease-causing variants in ABCA4 (OMIM 601691), enrolled in the study from 9 centers between August 2, 2013, and December 12, 2014; of these patients, 215 had at least 2 gradable fundus autofluorescence images with atrophic lesion(s) present in at least 1 eye. Exposures: Areas of definitely decreased autofluorescence (DDAF) and questionably decreased autofluorescence were quantified by a reading center. Progression rates were estimated from linear mixed models with time as the independent variable. Main Outcomes and Measures: Yearly rate of progression using the growth of atrophic lesions measured by fundus autofluorescence. Results: A total of 251 participants (458 study eyes) were enrolled. Images from 386 eyes of 215 participants (126 females and 89 males; mean [SD] age, 29.9 [14.7] years; mean [SD] age of onset of symptoms, 21.9 [13.3] years) showed atrophic lesions present on at least 2 visits and were graded for 2 (156 eyes), 3 (174 eyes), or 4 (57 eyes) visits. A subset of 224 eyes (123 female participants and 101 male participants; mean [SD] age, 33.0 [15.1] years) had areas of DDAF present on at least 2 visits; these eyes were included in the estimation of the progression of the area of DDAF. At the first visit, DDAF was present in 224 eyes (58.0%), with a mean (SD) lesion size of 2.2 (2.7) mm2. The total mean (SD) area of decreased autofluorescence (DDAF and questionably decreased autofluorescence) at first visit was 2.6 (2.8) mm2. Mean progression of DDAF was 0.51 mm2/y (95% CI, 0.42-0.61 mm2/y), and of total decreased fundus autofluorescence was 0.35 mm2/y (95% CI, 0.28-0.43 mm2/y). Rates of progression depended on the initial size of the lesion. Conclusions and Relevance: In Stargardt disease with DDAF lesions, fundus autofluorescence may serve as a monitoring tool for interventional clinical trials that aim to slow disease progression. Rates of progression depended mainly on initial lesion size.
Authors: Steffen Schmitz-Valckenberg; Almut Bindewald-Wittich; Joanna Dolar-Szczasny; Jens Dreyhaupt; Sebastian Wolf; Hendrik P N Scholl; Frank G Holz Journal: Invest Ophthalmol Vis Sci Date: 2006-06 Impact factor: 4.799
Authors: Vivienne C Greenstein; Ari D Schuman; Winston Lee; Tobias Duncker; Jana Zernant; Rando Allikmets; Donald C Hood; Janet R Sparrow Journal: Invest Ophthalmol Vis Sci Date: 2015-05 Impact factor: 4.799
Authors: R Theodore Smith; Nuno L Gomes; Gaetano Barile; Mihai Busuioc; Noah Lee; Andrew Laine Journal: Invest Ophthalmol Vis Sci Date: 2009-04-22 Impact factor: 4.799
Authors: Xiangrong Kong; Rupert W Strauss; Michel Michaelides; Artur V Cideciyan; José-Alain Sahel; Beatriz Muñoz; Sheila West; Hendrik P N Scholl Journal: Ophthalmology Date: 2016-07-02 Impact factor: 12.079
Authors: Laura Kuehlewein; Amir H Hariri; Alexander Ho; Laurie Dustin; Yulia Wolfson; Rupert W Strauss; Hendrik P N Scholl; SriniVas R Sadda Journal: Retina Date: 2016-06 Impact factor: 4.256
Authors: Maria A Parker; Dongseok Choi; Laura R Erker; Mark E Pennesi; Paul Yang; Elvira N Chegarnov; Peter N Steinkamp; Catherine L Schlechter; Claire-Marie Dhaenens; Saddek Mohand-Said; Isabelle Audo; Jose Sahel; Richard G Weleber; David J Wilson Journal: Transl Vis Sci Technol Date: 2016-10-01 Impact factor: 3.283
Authors: Peter Y Zhao; Maria Fernanda Abalem; Daniel Nadelman; Cynthia X Qian; Kari Branham; Dana Schlegel; Naheed Khan; John R Heckenlively; Thiran Jayasundera Journal: Am J Ophthalmol Date: 2017-12-27 Impact factor: 5.258
Authors: Etienne M Schönbach; Rupert W Strauss; Beatriz Muñoz; Yulia Wolfson; Mohamed A Ibrahim; David G Birch; Eberhart Zrenner; Janet S Sunness; Michael S Ip; SriniVas R Sadda; Sheila K West; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2020-07-01 Impact factor: 7.389
Authors: Xiangrong Kong; Kaoru Fujinami; Rupert W Strauss; Beatriz Munoz; Sheila K West; Artur V Cideciyan; Michel Michaelides; Mohamed Ahmed; Ann-Margret Ervin; Etienne Schönbach; Janet K Cheetham; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Frederick T Collison; Winston Lee; Gerald A Fishman; Jason C Park; Jana Zernant; J Jason McAnany; Rando Allikmets Journal: Retina Date: 2019-12 Impact factor: 4.256
Authors: Lijuan Chen; Winston Lee; Jose Ronaldo Lima de Carvalho; Stanley Chang; Stephen H Tsang; Rando Allikmets; Janet R Sparrow Journal: Sci Rep Date: 2019-04-23 Impact factor: 4.379
Authors: Jacque L Duncan; Eric A Pierce; Amy M Laster; Stephen P Daiger; David G Birch; John D Ash; Alessandro Iannaccone; John G Flannery; José A Sahel; Donald J Zack; Marco A Zarbin Journal: Transl Vis Sci Technol Date: 2018-07-18 Impact factor: 3.283